Cell line · CVCL_1395
M14
Cancer cell line, Homo sapiens. Amelanotic melanoma. 56 papers.
4 sourcescell-lines-2026-11-14-0.1.0
Download JSON
Cite this record
ConductScience Library. M14. Cell lines, record CVCL_1395. Release cell-lines-2026-11-14-0.1.0, 14 Nov 2026. https://conductscience.org/library/cell-lines/CVCL_1395
On this page
Cell line
As Cellosaurus gives it.
- Name
- M14
- Accession
- CVCL_1395
- RRID
- RRID:CVCL_1395
- Synonyms
- M14-MEL, UCLA-SO-M14, UCLA SO M14, UCLA-SO-14, UCLASO-M14, Melanoma 14, M-14
- Species
- Homo sapiens (Human)
- Sex
- Male
- Age at sampling
- 33Y
- Category
- Cancer cell line
- Diseases
- Amelanotic melanoma (NCIt C3802)
- Derived from
- Right buttock, hypodermis (metastatic)
- Entry created
- 2012-04-04
- Entry updated
- 2026-06-25
Source Cellosaurus
Problems0
Cellosaurus records no problem for this cell line.
None in this release.
Papers56
| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| BGN/MDK Axis in the Melanoma Tumor Microenvironment Strengthens Tumor Malignancy by Modulating Cancer Cells and Cancer-Associated Fibroblasts Crosstalk. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Circulating memory B-cell receptor repertoire analysis identifies novel candidate antibodies against metastatic melanoma in immunotherapy-responsive patients. | Front Immunol | 2025 | Its Methods give the RRID and name the line | PubMed | |
| In vitro detection of canine anti-human antibodies following intratumoral injection of the hu14.18-IL2 immunocytokine in spontaneous canine melanoma. | PLoS One | 2025 | Its Methods give the RRID and name the line | PubMed | |
| HTS384 NCI60: The Next Phase of the NCI60 Screen. | Cancer Res | 2024 | Cellosaurus cites it, and its Methods give the RRID and name the line | PubMed | |
| Susceptibility of Melanoma Cells to Targeted Therapy Correlates with Protection by Blood Neutrophils. | Cancers (Basel) | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Bioinformatics-based analysis reveals elevated CYTL1 as a potential therapeutic target for BRAF-mutated melanoma. | Front Cell Dev Biol | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Targeting tumor vasculature to improve antitumor activity of T cells armed ex vivo with T cell engaging bispecific antibody. | J Immunother Cancer | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Overcoming tumor heterogeneity by ex vivo arming of T cells using multiple bispecific antibodies. | J Immunother Cancer | 2022 | Its Methods give the RRID and name the line | PubMed | |
| Modulating tumor infiltrating myeloid cells to enhance bispecific antibody-driven T cell infiltration and anti-tumor response. | J Hematol Oncol | 2021 | Its Methods give the RRID and name the line | PubMed | |
| Quantitative Proteome Landscape of the NCI-60 Cancer Cell Lines. | iScience | 2019 | Cellosaurus cites it | PubMed |
1 to 10 of 56
See all 56 papersRelatives14
| Relation | Cell line | Accession | Problem | Source |
|---|---|---|---|---|
| Derived from it | BHP 14-9 | CVCL_6279 | Has a recorded problem | Cell lines |
| Derived from it | BHP 15-3 | CVCL_6280 | Has a recorded problem | Cell lines |
| Derived from it | BHP 17-10 | CVCL_6281 | Has a recorded problem | Cell lines |
| Derived from it | BHP 18-21 | CVCL_6282 | Has a recorded problem | Cell lines |
| Derived from it | BHP 5-16 | CVCL_6284 | Has a recorded problem | Cell lines |
| Derived from it | COLO 38 | CVCL_3934 | Has a recorded problem | Cell lines |
| Derived from it | M14-A | CVCL_A779 | Cell lines | |
| Derived from it | M14-CDM | CVCL_ZZ71 | Cell lines | |
| Derived from it | MDA-MB-435 | CVCL_0417 | Has a recorded problem | Cell lines |
| Derived from it | MuM-2C | CVCL_3448 | Has a recorded problem | Cell lines |
1 to 10 of 14
See all 14 relativesCell banks2
| Cell bank | Catalog number | Status | Source |
|---|---|---|---|
| CLS | 302163 | CLS | |
| NCI-DCTD | M14 | Cellosaurus |
Data dates
The date of each source this release read.
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this cell line from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_1395
GET https://conductscience.org/api/cell-lines/v1/CVCL_1395/papers?page=2